Creative Biolabs has announced a significant expansion of its advanced single-cell multi-omics and RNA sequencing solutions, a move that promises to accelerate biomedical discovery by providing researchers with more comprehensive tools to dissect cellular heterogeneity at unprecedented resolution. The upgraded suite of services, which ranges from single-cell transcriptome profiling to integrated multimodal and multi-omics workflows, is designed to meet the escalating demand for high-resolution cellular profiling across oncology, immunology, and neuroscience.
As life science research increasingly shifts from bulk tissue profiling to single-cell resolution, the ability to identify rare cell subpopulations, characterize complex tumor microenvironments, and trace cell lineage trajectories has become essential. Creative Biolabs now offers robust, high-throughput single-cell RNA sequencing services that deliver high sensitivity and coverage across thousands of individual cells, providing high-resolution transcriptomic insights from diverse fresh biological specimens.
A key challenge in single-cell research has been the processing of complex, fibrous, or biobanked archival samples, where traditional dissociation methods can cause cell damage, stress responses, or selective loss of fragile cell types. To address this, Creative Biolabs has introduced specialized single-nucleus RNA sequencing (snRNA-seq) capabilities. For tissues such as human brain, myocardium, or flash-frozen clinical biopsies, the company provides an optimized single-cell nuclei RNA sequencing service. By isolating intact nuclei, this approach bypasses harsh enzymatic dissociation, minimizes artifacts, and retains informative nuclear RNA profiles, thereby dramatically expanding the scope of clinical translational research.
Recognizing that cellular identity is orchestrated across multiple regulatory layers, Creative Biolabs has also advanced its high-throughput single-cell multi-omics service. This integrated platform allows simultaneous interrogation of genomic variations, epigenomic landscapes such as chromatin accessibility, cell surface proteomics (CITE-seq), and transcriptomes within identical single cells. By directly linking epigenetic regulation and genomic alterations to gene expression readouts, the service enables researchers to construct multi-dimensional cellular atlases and uncover novel therapeutic targets with greater biological clarity.
"Understanding biology at single-cell and single-nucleus resolution is no longer a luxury—it is fundamental to precision medicine and biomarker discovery," said a senior scientist at Creative Biolabs. "Our goal is to provide researchers with a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support."
The implications of this expansion are substantial. By offering end-to-end solutions that span sample preparation, sequencing, and bioinformatics, Creative Biolabs is lowering the technical barriers that have historically limited the adoption of single-cell technologies. This is particularly important for translational research, where clinical samples are often limited, fragile, or archived. The ability to extract meaningful data from such samples can accelerate the identification of biomarkers and therapeutic targets, ultimately advancing precision medicine.
Supported by advanced microfluidics technologies, stringent quality control benchmarks, and tailored bioinformatics pipelines, Creative Biolabs continues to partner with academic and biopharmaceutical research teams worldwide to unravel the complexities of human disease. For more information about Creative Biolabs and its full suite of single-cell analytical solutions, please visit https://singlecell.creative-biolabs.com/.
